Biogenic metal nanoparticles as a potential class of antileishmanial agents: mechanisms and molecular targets

Nanomedicine (Lond). 2020 Apr;15(8):809-828. doi: 10.2217/nnm-2019-0413. Epub 2020 Mar 24.

Abstract

Leishmaniasis, a category 1 disease, has remained neglected for decades, and therefore, has developed into a severe health problem worldwide. Unfortunately, the available antileishmanial drugs are limited, and the parasites have shown an inevitable resistance toward most of these drugs. All these factors pose a barrier to control the parasite at present. Hence, new strategies are needed to develop more effective and less toxic nanomedicines that could treat and manage the Leishmania parasite. One of these effective strategies is to construct nanometals with biologically active molecules that could possess dynamic antileishmanial activities with desirable biocompatibility. In this review paper, antileishmanial potencies of different metal nanoparticles, with particular emphasis on biogenic metal nanoparticles from 2011 to 2019, are summarized. The mechanisms by which metal-based nanomedicines kill Leishmania are also discussed.

Keywords: Leishmania; green synthesis; mechanisms; metal nanoparticles; molecular targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiprotozoal Agents* / pharmacology
  • Humans
  • Leishmania*
  • Leishmaniasis* / drug therapy
  • Metal Nanoparticles*

Substances

  • Antiprotozoal Agents